The Most Overlooked Drug on the Metro Map

Beyond the Metro Map | Jane McLelland

Nothing in this article constitutes medical advice. The science discussed is published, peer-reviewed research. Its application to any individual’s treatment decisions requires a qualified clinician who can assess their specific circumstances.

The most dangerous mistake in integrative oncology is not choosing the wrong agent.

It is thinking that one agent is ever enough.

I have been saying this for years, and I will keep saying it because the pull toward single-agent thinking is almost irresistible. Someone reads about statins in cancer — and there is solid evidence for statins, I am not dismissing it — so they start a statin. They feel like they have addressed the lipid biology. They move on.

They haven’t. The cancer cell hasn’t moved on.

The moment you suppress one pathway, the cancer cell is already working around it. The mevalonate pathway is not a single pipe. It is a system with sensors and compensatory relays and redundant supply routes, and the cancer cell’s response to pharmaceutical pressure is to activate every one of them simultaneously. The statin suppresses HMGCR. The cell senses the drop in intracellular cholesterol and fires SCAP-SREBP2 signalling to transcribe more HMGCR. The statin effect is being actively counteracted by the very mechanism it triggers.